Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer.

Giebel S, Boratyn-Nowicka A, Karabon L, Jedynak A, Pamula-Pilat J, Tecza K, Kula D, Kowal M, Frydecka I, Grzybowska E.

Hum Immunol. 2014 Jun;75(6):508-13. doi: 10.1016/j.humimm.2014.04.002. Epub 2014 Apr 19.

PMID:
24755350
2.

Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.

Hilton HG, Guethlein LA, Goyos A, Nemat-Gorgani N, Bushnell DA, Norman PJ, Parham P.

J Immunol. 2015 Oct 1;195(7):3160-70. doi: 10.4049/jimmunol.1501358. Epub 2015 Aug 26.

3.

Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis.

Littera R, Chessa L, Onali S, Figorilli F, Lai S, Secci L, La Nasa G, Caocci G, Arras M, Melis M, Cappellini S, Balestrieri C, Serra G, Conti M, Zolfino T, Casale M, Casu S, Pasetto MC, Barca L, Salustro C, Matta L, Scioscia R, Zamboni F, Faa G, Orrù S, Carcassi C.

PLoS One. 2016 Jan 8;11(1):e0146086. doi: 10.1371/journal.pone.0146086. eCollection 2016.

4.

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.

Keating SE, Ní Chorcora C, Dring MM, Stallings RL, O'Meara A, Gardiner CM.

Tissue Antigens. 2015 Sep;86(3):172-7. doi: 10.1111/tan.12608. Epub 2015 Jul 22.

PMID:
26202659
5.

Killer immunoglobulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population.

Sanjeevi S, Sun C, Kanungo A, Sanjeevi CB.

Diabet Med. 2016 Jan;33(1):91-6. doi: 10.1111/dme.12815. Epub 2015 Jul 2.

PMID:
26031759
6.

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.

de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F.

Liver Transpl. 2009 Apr;15(4):390-9. doi: 10.1002/lt.21673.

7.

Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors.

Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE.

Hum Immunol. 2010 Oct;71(10):976-81. doi: 10.1016/j.humimm.2010.06.019. Epub 2010 Jun 30.

PMID:
20600442
8.

Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.

Cassidy S, Mukherjee S, Myint TM, Mbiribindi B, North H, Traherne J, Mulder A, Claas FH, Purbhoo MA, Das J, Khakoo SI.

Eur J Immunol. 2015 Feb;45(2):492-500. doi: 10.1002/eji.201444613. Epub 2014 Nov 29.

9.

Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B.

Gao X, Jiao Y, Wang L, Liu X, Sun W, Cui B, Chen Z, Zhao Y.

Clin Immunol. 2010 Oct;137(1):139-46. doi: 10.1016/j.clim.2010.05.011.

PMID:
20643584
10.

Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.

David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, Cesbron A, Retière C.

J Immunol. 2013 Nov 1;191(9):4778-88. doi: 10.4049/jimmunol.1301580. Epub 2013 Sep 27.

11.

Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals.

Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M.

Cancer Immunol Immunother. 2005 Feb;54(2):172-8. Epub 2004 Jul 10.

PMID:
15248031
12.

Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells.

Charoudeh HN, Schmied L, Gonzalez A, Terszowski G, Czaja K, Schmitter K, Infanti L, Buser A, Stern M.

Immunogenetics. 2012 Oct;64(10):739-45. doi: 10.1007/s00251-012-0633-1. Epub 2012 Jul 7.

PMID:
22772778
13.

The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression.

Kandilarova SM, Paschen A, Mihaylova A, Ivanova M, Schadendorf D, Naumova E.

Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):73-81. doi: 10.1007/s00005-016-0437-3. Epub 2017 Jan 12.

PMID:
28083606
14.

Resurrecting KIR2DP1: A Key Intermediate in the Evolution of Human Inhibitory NK Cell Receptors That Recognize HLA-C.

Hilton HG, Blokhuis JH, Guethlein LA, Norman PJ, Parham P.

J Immunol. 2017 Mar 1;198(5):1961-1973. doi: 10.4049/jimmunol.1601835. Epub 2017 Jan 25.

15.

Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3.

Roberts CH, Molina S, Makalo P, Joof H, Harding-Esch EM, Burr SE, Mabey DC, Bailey RL, Burton MJ, Holland MJ.

PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2744. doi: 10.1371/journal.pntd.0002744. eCollection 2014 Mar.

16.
17.

Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.

Alomar SY, Alkhuriji A, Trayhyrn P, Alhetheel A, Al-Jurayyan A, Mansour L.

Immunogenetics. 2017 Feb;69(2):69-76. doi: 10.1007/s00251-016-0950-x. Epub 2016 Sep 15.

PMID:
27631728
18.

KIR gene mismatching and KIR/C ligands in liver transplantation: consequences for short-term liver allograft injury.

Legaz I, López-Álvarez MR, Campillo JA, Moya-Quiles MR, Bolarín JM, de la Peña J, Salgado G, Gimeno L, García-Alonso AM, Muro M, Miras M, Alonso C, Álvarez-López MR, Minguela A.

Transplantation. 2013 Apr 27;95(8):1037-44. doi: 10.1097/TP.0b013e318286486c.

PMID:
23478359
19.

Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn's disease.

Díaz-Peña R, Vidal-Castiñeira JR, Moro-García MA, Alonso-Arias R, Castro-Santos P.

Hum Immunol. 2016 Jan;77(1):104-109. doi: 10.1016/j.humimm.2015.10.020. Epub 2015 Nov 2.

PMID:
26542067
20.

Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission.

Jennes W, Verheyden S, Mertens JW, Camara M, Seydi M, Dieye TN, Mboup S, Demanet C, Kestens L.

Blood. 2013 Feb 14;121(7):1157-64. doi: 10.1182/blood-2012-09-455352. Epub 2012 Dec 13.

Supplemental Content

Support Center